TRexBio to Present Late-Breaking Data at SID 2026 Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis ...
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results